The clinical trial system wasn't designed with speed or small research institutions in mind, and the system is "too siloed, too bureaucratic, and in many cases too slow," as well as lacks communication and coordination, says FasterCures Executive Director Esther Krofah. The FDA and institutional review boards have tried to be more responsive and flexible on studies related to COVID-19, but even studies of already approved generic drugs have been difficult to get off the ground.
Pandemic highlights need for nimble clinical trial system
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.